Novo Nordisk A/S (NVO) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Novo Nordisk A/S (NYSE: NVO) recently:

  • 12/2/2018 – Novo Nordisk A/S had its “buy” rating reaffirmed by analysts at UBS Group AG.
  • 11/29/2018 – Novo Nordisk A/S had its “hold” rating reaffirmed by analysts at Kepler Capital Markets.
  • 11/26/2018 – Novo Nordisk A/S had its “sell” rating reaffirmed by analysts at HSBC Holdings plc.
  • 11/26/2018 – Novo Nordisk A/S was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Novo Nordisk reported in line earnings but beat sales estimates in third-quarter 2018. Novo Nordisk’s continued growth from Victoza and Tresiba as well as higher contributions from Saxenda and Xultophy are likely to be partly offset by the impact of lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition within the diabetes and biopharmaceuticals markets, besides macroeconomic conditions in many markets under International Operations. However, the company remains optimistic about Ozempic and results for oral semaglutide and is looking forward to make the first oral GLP-1 treatment available for people with type II diabetes. Shares of the company have underperformed the industry, year to date. “
  • 11/26/2018 – Novo Nordisk A/S had its “buy” rating reaffirmed by analysts at UBS Group AG.
  • 11/26/2018 – Novo Nordisk A/S was upgraded by analysts at Pareto Securities from a “hold” rating to a “buy” rating.
  • 11/20/2018 – Novo Nordisk A/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Novo Nordisk reported in line earnings but beat sales estimates in third-quarter 2018. However, the company remains optimistic about Ozempic and results for oral semaglutide. It is looking forward to make the first oral GLP-1 treatment available for people with type II diabetes. The company also made someorganizational changes aimed at boosting innovation in its R&D organization and redirecting resources in other parts of the organization to drive growth further. The company’s acquisition of Ziylo will provide it with the latter’s synthetic glucose binding molecules that will enable it todevelop glucose responsive insulins. The company’s expansion of its biopharm business also bodes well.Shares of the company underperformed the industry year to date.”
  • 11/19/2018 – Novo Nordisk A/S was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating.
  • 11/6/2018 – Novo Nordisk A/S had its “sell” rating reaffirmed by analysts at HSBC Holdings plc.
  • 11/2/2018 – Novo Nordisk A/S had its “hold” rating reaffirmed by analysts at Cfra.
  • 10/27/2018 – Novo Nordisk A/S was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 10/18/2018 – Novo Nordisk A/S had its “hold” rating reaffirmed by analysts at Kepler Capital Markets.
  • 10/10/2018 – Novo Nordisk A/S was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “sell” rating. According to Zacks, “Novo Nordisk’s continued growth from Victoza and Tresiba as well as higher contributions from Saxenda and Xultophy are likely to be partly offset by the impact of lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition within the diabetes and biopharmaceuticals markets, besides macroeconomic conditions in many markets under International Operations. However, the company remains optimistic about Ozempic and results for oral semaglutide and is looking forward to make the first oral GLP-1 treatment available for people with type II diabetes. Shares of the company have underperformed the industry, year to date. Estimates have remained stable ahead of the Q3 earnings release and the company has a positive record of earnings surprises in recent quarters.”
  • 10/8/2018 – Novo Nordisk A/S was downgraded by analysts at Bank of America Corp from a “buy” rating to a “neutral” rating.
  • 10/8/2018 – Novo Nordisk A/S is now covered by analysts at Guggenheim. They set a “buy” rating on the stock.
  • 10/5/2018 – Novo Nordisk A/S was downgraded by analysts at Pareto Securities from a “buy” rating to a “hold” rating.

NYSE:NVO opened at $46.04 on Tuesday. Novo Nordisk A/S has a 12-month low of $41.23 and a 12-month high of $58.37. The stock has a market capitalization of $113.92 billion, a P/E ratio of 19.68, a price-to-earnings-growth ratio of 2.46 and a beta of 0.75.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.58 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.58. Novo Nordisk A/S had a net margin of 34.94% and a return on equity of 81.50%. The firm had revenue of $4.31 billion during the quarter, compared to analyst estimates of $4.11 billion. Analysts expect that Novo Nordisk A/S will post 2.45 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Clearbridge Investments LLC raised its position in Novo Nordisk A/S by 46.7% in the third quarter. Clearbridge Investments LLC now owns 644,557 shares of the company’s stock worth $30,384,000 after purchasing an additional 205,326 shares in the last quarter. Carnegie Capital Asset Management LLC increased its holdings in shares of Novo Nordisk A/S by 5.4% during the third quarter. Carnegie Capital Asset Management LLC now owns 109,296 shares of the company’s stock worth $4,836,000 after buying an additional 5,557 shares in the last quarter. Matthew Goff Investment Advisor LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $819,000. NorthCoast Asset Management LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $2,503,000. Finally, Banco de Sabadell S.A increased its holdings in shares of Novo Nordisk A/S by 26.3% during the third quarter. Banco de Sabadell S.A now owns 81,355 shares of the company’s stock worth $3,850,000 after buying an additional 16,964 shares in the last quarter. 6.84% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Featured Story: Compound Interest

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit